Skip to main content
. 2018 Dec 21;9(100):37352–37366. doi: 10.18632/oncotarget.26424

Figure 3. Effect of high-dose palbociclib on total RB.

Figure 3

A. H358 NSCLC cells were treated for 24 and 72 hours with palbociclib (97 nM and 2.5 µM) and/or the proteasome inhibitor MG132 (1.0 µM), and their effect on total RB protein and phosphorylated RB (P-RB) was determined by immunoblot analysis. Each blot is representative of two independent experiments. B. Postulated mechanism of the dosage effect of palbociclib on total RB concentrations. At low concentrations of palbociclib, inhibition of CDK4/6 leads to selective inhibition of RB phosphorylation. A high concentration of palbociclib was associated with proteasomal degradation of total RB.